Oxurion nv – publication in progress in retinal eye research highlights the potential of pan-rgd integrin antagonists to improve the treatment of diabetic retinopathy and wet amd

Oxurion is a leader in the development of pan-rgd integrin antagonists for retinal vascular disorders - thr-687 on track to enter phase 2 development by mid-year

BCYC Ratings Summary

BCYC Quant Ranking